Revive
Therapeutics
Approved
to Trade on the OTCQB Market
TORONTO,
June 25,
2021 -- InvestorsHub NewsWire -- Revive Therapeutics
Ltd. ("Revive" or the "Company") (CSE: RVV, USA: RVVTF, FRANKFURT:
31R), a specialty life
sciences company focused on the research and development of
therapeutics for medical needs and rare disorders,
is
pleased to announce that its common
shares have been approved for trading on the
OTCQB®
Market
("OTCQB") effective Monday June
28,
2021.
The
Company's U.S. listing will trade under the symbol
"RVVTF"
while the Company's primary Canadian listing will continue to trade
on the Canadian Securities Exchange under "RVV".
Michael
Frank, CEO of the
Company commented, "We are focused on completing
our
Phase 3 study in COVID-19 with
the aim to seek EUA
approval from the FDA
for
Bucillamine
in the
treatment of mild to moderate COVID-19 patients,
and
advancing
our proprietary
psychedelics
program in
developing
novel
uses and delivery forms of psilocybin to treat mental
health and substance abuse disorders. With our common
shares listed on the OTCQB it will help us to broaden our awareness
and shareholder base with institutional and retail investors in the
U.S."
Investors can find
real-time quotes and market information on the Company at
https://www.otcmarkets.com/stock/RVVTF/overview.
About
Revive Therapeutics Ltd.
Revive
is a life sciences company focused on the research and development
of therapeutics for infectious diseases and rare disorders, and it
is prioritizing drug development efforts to take advantage
of several regulatory incentives awarded by the FDA such as Orphan
Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease
designations. Currently, the Company is exploring the use of
Bucillamine for the potential treatment of infectious diseases,
with an initial focus on severe influenza and COVID-19. With its
recent acquisition of Psilocin Pharma Corp., Revive is advancing
the development of Psilocybin-based therapeutics in various
diseases and disorders. Revive's cannabinoid pharmaceutical
portfolio focuses on rare inflammatory diseases and the company was
granted FDA orphan drug status designation for the use of
Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and
to treat ischemia and reperfusion injury from organ
transplantation. For more information, visit
www.ReviveThera.com.
For
more information, please contact:
Michael
Frank
Chief
Executive Officer
Revive
Therapeutics Ltd.
Tel: 1
888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com
Neither the Canadian Securities Exchange nor its Regulation
Services Provider has reviewed or accepts responsibility for the
adequacy or accuracy of this release.
Cautionary Statement
This press release contains 'forward-looking information' within
the meaning of applicable Canadian securities legislation. These
statements relate to future events or future performance. The use
of any of the words "could", "intend", "expect", "believe", "will",
"projected", "estimated" and similar expressions and statements
relating to matters that are not historical facts are intended to
identify forward-looking information and are based on Revive's
current belief or assumptions as to the outcome and timing of such
future events. Forward looking information in this press release
includes information with respect to the
Company's cannabinoids, psychedelics and infectious diseases
programs.
Forward-looking information is based on reasonable assumptions that
have been made by Revive at the date of the information and is
subject to known and unknown risks, uncertainties, and other
factors that may cause actual results or events to differ
materially from those anticipated in the forward-looking
information. Given these risks, uncertainties and assumptions, you
should not unduly rely on these forward-looking statements. The
forward-looking information contained in this press release is made
as of the date hereof, and Revive is not obligated to update or
revise any forward-looking information, whether as a result of new
information, future events or otherwise, except as required by
applicable securities laws. The foregoing statements expressly
qualify any forward-looking information contained herein. Reference
is made to the risk factors disclosed under the heading "Risk
Factors" in the Company's annual MD&A for the fiscal year ended
June 30, 2020, which has been filed on SEDAR and is available under
the Company's profile at www.sedar.com.